Literature DB >> 17632733

Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer.

Yiqun Zhang1, Xinyu Qin, Yanhong Zhang, Lili Zhao, Yigang Wang, Xinyuan Liu, Liqing Yao.   

Abstract

PURPOSE: ZD55-MnSOD is an E1B 55 kDa-deleted replication-competent adenovirus and armed with the therapeutic gene MnSOD. The expression of the therapeutic gene MnSOD increases with the selective replication of the oncolytic adenovirus (ZD55) so that ZD55-MnSOD has more significant activity than the replicate defective adenovirus Ad-MnSOD in vitro and in vivo. The tumor cannot be completely eradicated only with ZD55-MnSOD, although ZD55-MnSOD has obvious antitumor activity. 5-fluorouracil (5-FU) is still the most effective adjuvant therapy for patients with colorectal cancer.
METHODS: We reasoned that combined treatment of cancer cells with ZD55-MnSOD and 5-FU might have a synergistic effect. In vitro experiments with SW620 colorectal carcinoma cell line demonstrated that it was sensitive to ZD55-MnSOD, especially most sensitive to ZD55-MnSOD plus 5-FU treatment. Treatment with both ZD55-MnSOD and 5-FU could induce more significant apoptosis in cancer cells compared with ZD55-MnSOD or 5-FU alone, respectively. A better antitumor activity was observed by ZD55-MnSOD plus 5-fluorouracil (5-FU) treatment. Tumor growth was greatly inhibited by this combined treatment, and animal survival time increased.
CONCLUSION: These results show that, by using the combination therapies, a significant decrease in tumor mass can be achieved, which suggest that ZD55-MnSOD in combination with 5-FU may have potential clinical implications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17632733     DOI: 10.1007/s00432-007-0273-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  SOD2: a new type of tumor-suppressor gene?

Authors:  A Bravard; L Sabatier; F Hoffschir; M Ricoul; C Luccioni; B Dutrillaux
Journal:  Int J Cancer       Date:  1992-05-28       Impact factor: 7.396

Review 2.  Redox regulation of transcriptional activators.

Authors:  Y Sun; L W Oberley
Journal:  Free Radic Biol Med       Date:  1996       Impact factor: 7.376

3.  Inhibition of cell growth and sensitization to oxidative damage by overexpression of manganese superoxide dismutase in rat glioma cells.

Authors:  W Zhong; L W Oberley; T D Oberley; T Yan; F E Domann; D K St Clair
Journal:  Cell Growth Differ       Date:  1996-09

4.  Activation of a human Ste20-like kinase by oxidant stress defines a novel stress response pathway.

Authors:  C M Pombo; J V Bonventre; A Molnar; J Kyriakis; T Force
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

5.  Potential mechanisms for the inhibition of tumor cell growth by manganese superoxide dismutase.

Authors:  K H Kim; A M Rodriguez; P M Carrico; J A Melendez
Journal:  Antioxid Redox Signal       Date:  2001-06       Impact factor: 8.401

6.  Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model.

Authors:  Y Zhao; Y Xue; T D Oberley; K K Kiningham; S M Lin; H C Yen; H Majima; J Hines; D St Clair
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

7.  Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta.

Authors:  R Chinery; J A Brockman; M O Peeler; Y Shyr; R D Beauchamp; R J Coffey
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

8.  Tracheal insufflation of tumor necrosis factor protects rats against oxygen toxicity.

Authors:  M F Tsan; J E White; T A Santana; C Y Lee
Journal:  J Appl Physiol (1985)       Date:  1990-03

9.  An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.

Authors:  Zifei Pei; Liang Chu; Weiguo Zou; Zilai Zhang; Songbo Qiu; Rong Qi; Jinfa Gu; Cheng Qian; Xinyuan Liu
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

10.  MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells.

Authors:  Hong Duan; Hannah J Zhang; Ji-Qin Yang; Larry W Oberley; Bernard W Futscher; Frederick E Domann
Journal:  Antioxid Redox Signal       Date:  2003-10       Impact factor: 8.401

View more
  6 in total

1.  Dietary trace element intake and liver cancer risk: Results from two population-based cohorts in China.

Authors:  Xiao Ma; Yang Yang; Hong-Lan Li; Wei Zheng; Jing Gao; Wei Zhang; Gong Yang; Xiao-Ou Shu; Yong-Bing Xiang
Journal:  Int J Cancer       Date:  2016-11-27       Impact factor: 7.396

Review 2.  Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.

Authors:  Sonia Tusell Wennier; Jia Liu; Grant McFadden
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

3.  Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24.

Authors:  Lianli Xiao; Xin Li; Na Niu; Jing Qian; Guoliang Xie; Yigang Wang
Journal:  Mol Cell Biochem       Date:  2010-02-18       Impact factor: 3.396

Review 4.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

5.  Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus.

Authors:  Liangshun You; Ying Wang; Yingming Jin; Wenbin Qian
Journal:  Oncol Rep       Date:  2012-01-16       Impact factor: 3.906

6.  Combination therapy with F5/35 fiber chimeric conditionally replicative adenoviruses expressing IL-24 enhances the antitumor effect of temozolomide against melanoma.

Authors:  Ming Yang; Chunsheng Yang; Yingkai Tao; Jianqin Tang; Qian Huang; Wenwen Guo; Shouxin Feng; Aijun Jiang; Xifeng Xu; Guan Jiang; Yanqun Liu
Journal:  Cancer Med       Date:  2018-11-08       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.